Navigation Links
At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site
Date:11/24/2014

Baltimore, MD (PRWEB) November 24, 2014

Continental Clinical Solutions, LLC (Continental) focuses on recruiting underrepresented patient populations into clinical trials at its mid-Atlantic late-phase research facility, located in Baltimore, Maryland.

“Continental was created with the idea of closing patient disparities in mind. Clinical trials play a fundamental role in medical advances," said Continental's CEO, Saleh Stevens. "From the Tuskegee syphilis experiment to the immortal cell line of Henrietta Lacks, dubious ethical practices and on-going safety concerns have plagued recruitment in the minority segment for clinical trials in the US and abroad." The exclusion of large patient populations from clinical trials adversely impacts scientific advances.

Almost 40% of registered clinical studies occur in the United States, equaling an approximate 66,700 clinical trials. The number of trials in the US increased by almost 16% since 2013, according to ClinicalTrials.gov, a website dedicated to information on clinical studies registered with the FDA. Despite the increase in studies, the percentage of the US population participating in studies has remained stagnant at 6%.

“When you further distill that 6%, you find minorities in late phase studies are terribly underrepresented. Underrepresentation means missed opportunities to address specific genomics and other criteria that will influence drug efficacy in the specific populations, sentencing future generations to inadequate medical remedies," Stevens added.

Though mistrust is a large obstacle in diversity in recruitment, insurance and cost of care continue to play a role in stymying minority recruitment into trials. Many unapproved treatments have been reserved solely for patients who can afford to pay out of pocket for travel and study-related healthcare needs. Those costs can vary from hundreds to tens of thousands of dollars, according to a report commissioned by the Pharmaceutical Researchers and Manufacturers of America. Previously, many insurers excluded healthcare related to certain phases of clinical trials under "experimental" and "investigational" exclusions in their policies. These exclusions, when triggered, not only denied reimbursement of trial-related healthcare costs, but sometimes resulted in policy cancellation—an untenable circumstance for patients already leery of joining studies.

Beginning January 1, 2014, the Affordable Care Act set forth legislative changes impacting some of the cost issues patients face when considering clinical trials. The resulting federal laws ensured that new health insurance plans cover routine care costs for people taking part in clinical trials. Insurers are no longer permitted to drop coverage because of patient participation in a clinical trial. Maryland, among a few other states, has been ahead of the curve with covering significant costs associated with clinical trials, with legislation dating as far back as 1998.

"With the connectivity that social media platforms afford us, it is incumbent upon us to communicate the changing landscape to patient populations who are left either unaware or out of the study pipeline," Stevens concluded as he reiterated Continental’s commitment to reducing disparities in clinical trial patient populations at its Maryland site.

Continental Clinical Solutions, LLC is a multi-therapeutic dedicated research clinic providing turnkey clinical trial sites for community practitioners in all trial phases, bringing diverse patient populations and industry pharmaceutical companies together. Visit Continental Clinical Solutions at http://www.continentalclinical.com.

Read the full story at http://www.prweb.com/releases/ContinentalClinicalMD/SalehStevens/prweb12323817.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dr. Adrienne C. Scheck, Ph.D. is recognized by Continental Whos Who as a Pinnacle Professional
2. F. David Rollo, MD, Ph.D., FACC, FACNP is recognized by Continental Whos Who as a Pinnacle Professional
3. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
4. Positive Clinical Study Results for BSPs HyperQ Technology
5. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
9. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
10. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
11. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2018)... ... September 06, 2018 , ... Akadeum Life Sciences today announced ... career as an executive and leader of numerous biotech companies. , He most ... biologics company acquired by Thompson Street Capital in St. Louis, MO. Prior to ...
(Date:8/29/2018)... ... August 28, 2018 , ... ... spinal implants, announced today the successful completion of a $5.5 million funding round ... Purdue’s Foundry Investment Fund, Commenda Capital, and Ellipsis Ventures. , “Our investment in ...
(Date:8/29/2018)... ... August 28, 2018 , ... LabRoots , the ... the world, is proud to announce the launch of a new gamification feature, allowing ... chance to win one of LabRoots most popular shirts. , Throughout each month, LabRoots ...
(Date:8/23/2018)... ... August 22, 2018 , ... Crucial Data Solutions, Inc. ... it the first fully-featured app for electronic data capture (EDC) and electronic participant ... constitute 99 percent of the market share for mobile devices worldwide; in turn, ...
Breaking Biology Technology:
(Date:9/12/2018)... ... September 11, 2018 , ... Tennant ... introduce the new ChemXP™ line of high performance secondary containment coatings, designed to ... to provide Tennant Coatings’ elite certified installers with the needed solutions to protect ...
(Date:9/7/2018)... ... September 06, 2018 , ... Sensors Midwest ... show Sensors Expo & Conference , announces their partnership with Fraunhofer USA ... an IoT Enabled Industrial IoT Certification Program. Taking place on October 17, 2018 ...
(Date:8/31/2018)... and BOSTON, Mass. (PRWEB) , ... August 30, 2018 , ... ... Product and Customer Success. Jason has more than 20-years of telecommunications experience and over ... Sales at Appia Communications, which was acquired by CallTower in early 2018. , ...
Breaking Biology News(10 mins):